Oncology

Review top news and interview highlights from the week ending July 29, 2022.

The associate professor at Fred Hutch Cancer Center discussed next steps with the clinical trial being conducted Fred Hutch Cancer Center.

CYTO-102 is being developed by City of Hope and CytoImmune.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.

CYNK-101 has previously been granted fast track and orphan drug designation.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

All 3 patients remained progression-free at more than 1 year post-treatment.

Nilanjan Ghosh, MD, PhD, discussed the impact of liso-cel's approval.

In preclinical studies, OBX-115 demonstrated improved TIL persistence, potency, and tumor control compared with unengineered TILs.

The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.

The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.

The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.

Review top news and interview highlights from the week ending July 22, 2022.

WU-CART-007 has been granted fast track, rare pediatric disease, and orphan drug designations.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Ofra-vec continues to be evaluated in phase 2 trials for glioblastoma and colorectal cancer.

Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.

Lauren Veltri, MD Director, WVU Cancer Institute Hematopoietic Malignancy and Cellular Therapy Program, discussed the recent FACT accreditation.

Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.

Review top news and interview highlights from the week ending July 15, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SCG101 will be evaluated in trials across China, Singapore, and the US.

The chief program officer of the Alliance for Cancer Gene Therapy discussed the work the nonprofit is doing.

The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.

A phase 1 trial has completed enrollment in its first cohort and is now enrolling the second.